Table 1.

Gene‐Expression Profiles Are Altered More Significantly in the In Vitro NASH Model Than Under Steatosis Conditions

Pathway/Gene	Steatosis		NASH
	Fold Change	P Value	Fold Change	P Value
Insulin Signaling
IGF1	1.58	0.31	3.72	<0.01
IGFBP1	2.65	0.28	41.91	0.002
mTOR	1.25	0.07	0.26	<0.01
PKLR	1.36	0.15	0.14	<0.01
SOCS3	1.52	0.32	292.60	<0.01
Glucose Metabolism
G6PC	1.67	0.11	0.40	0.002
G6PDH	1.38	0.33	5.99	<0.01
GCK	1.46	0.34	0.10	<0.01
PDK4	4.33	0.02	1.56	0.086
Cholesterol Metabolism
ABCA1	0.99	0.94	1.97	0.032
CD36	1.25	0.76	167.67	<0.01
CYP2E1	5.02	0.02	7.56	0.016
CYP7A1	5.24	0.01	0.14	<0.01
PPARG	1.24	0.48	3.20	0.006
Lipid Metabolism
FABP3	1.70	0.33	6.73	<0.01
FABP5	1.40	0.14	13.42	<0.01
FASN	1.40	0.31	0.04	<0.01
GK	1.74	0.22	8.50	0.029
LPL	1.03	0.77	75.08	<0.01
SCD	1.06	0.90	0.16	<0.01
Inflammation
CEBPB	1.46	0.08	0.55	0.019
IFN‐$\gamma$	1.27	0.11	4.38	<0.01
IL‐10	1.27	0.11	6.66	<0.01
IL‐1B	0.43	0.08	10.12	<0.01
IL‐6	0.69	0.87	481.35	<0.01
TNF	1.44	0.43	10.79	<0.01

Abbreviations: ABCA1, ATP‐Binding Cassette, Sub‐Family A, Member 1; CD36, clusters of differentiation 36; CEBPB, CCAAT Enhancer Binding Protein Beta; CYP2E1, Cytochrome P450 Family 2 Subfamily E Member 1; CYP7A1, Cytochrome P450 Family 7 Subfamily A Member 1; FABP, fatty acid‐binding protein; FASN, Fatty Acid Synthase; G6P, glucose 6‐phosphate; G6PDH, glucose‐6‐phosphate dehydrogenase; GCK, Glucokinase; GK, Glycerol Kinase; IFN‐γ, interferon gamma; IGF1, insulin‐like growth factor 1; IGFBP1, insulin‐like growth factor‐binding protein 1; LPL, Lipoprotein Lipase; mTOR, mammalian target of rapamycin; PDK4, pyruvate dehydrogenase kinase isozyme 4; PKLR, Pyruvate Kinase R‐Type/L‐Type; PPAR‐$\gamma$, peroxisome proliferator‐activated receptor gamma; SCD, Stearoyl‐CoA Desaturase; and SOCS3, suppressor of cytokine signaling 3.